GeneDx Holdings Corp.
WGSHealthcareNASDAQDiagnostics & Research · Last scanned Oct 26, 2026
Scan Results
Daily timeframePart of the healthcare sector, GeneDx Holdings Corp. (WGS) is listed under Diagnostics & Research. At a $1.67B market cap, GeneDx Holdings Corp. ranks as a small-cap company within healthcare. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services.
Market Cap
$1.67B
Beta
1.97
P/E (TTM)
—
P/E (Fwd)
46.85
EPS (TTM)
$-3.63
EPS (Fwd)
$1.20
ROE
-40.8%
ROA
-7.9%
Cash
$132.5M
Total Debt
$167.4M
Free CF
-$47.5M
52W Change
-57.0%
Annual Financials
Cash vs Debt
Where WGS stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, WGS finished 5.76% below its 150-day moving average ($67.50) and 15.20% below its 200-day moving average ($75.01). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is WGS overbought or oversold?
At the October 19, 2026 close, WGS's RSI(14) was 25.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $132.5M in cash, though total debt stands at $167.4M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$47.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -40.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $234.7M (2022) to $427.5M (2025), reflecting a 82% increase over the period.
GeneDx Holdings Corp.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence GeneDx Holdings Corp.'s trajectory.